OLMA Olema Pharmaceuticals, Inc.

XNAS 7.22 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

OLMA $7.22 —

What changed

Recent filings, trades and moves
Key stats
$7.22
52-Week Range
$6.24 – $36.26
YTD
-71.42%
IV Rank (30D)
15.44
Straddle Price
$3.57
P/C Vol Ratio
2.90
Market Cap
$0.6B
Open
$7.29
Day Range
$7.07 – $7.33
Volume
20,782
Prev Close
$7.27
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.86%
Beta vs SPY1.43
Cost of Equity (CAPM)12.73% (VRP-adj)
WACC12.82%
Volatility Risk Premium+134.8pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-47.5%
Book / Price64.3% — banking bias active (P/B is primary)
Debt / Equity0.01
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$8.36 (Market Anchor value)
SMA 20 / Bollinger Mid$7.06
Bollinger Width / SMA2017.3% (drives anchor stability)
Net Debt$-0.0B
Market Cap$1B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
93%
20-Day Fair Value
≈ by Dec 10, 2026
$7.16
α +0.3% rank 83%
conviction
24%
40-Day Fair Value
≈ by Jan 8, 2027
$7.55
α +5.8% rank 90%
conviction
98%
60-Day Fair Value
≈ by Feb 8, 2027
$7.54
α +5.7% rank 87%
conviction
93%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 41.3× · 3 peers
Peer EV/EBITDA n/a 0% median 20.7× · 3 peers
Peer P/B $17.53 22% median 3.8× · 3 peers
Peer P/S n/a 0% median 4.0× · 3 peers
Market Anchor (SMA50) $8.36 78% stability 69% (BB-width)
Options Expected (B-L 30d) $7.40 0% 6 strikes · skew +0.18
As of 2026-11-11 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.6B
Employees
150
List Date
2020-11-19
CIK
0001750284
Last Earnings
Nov 9 after close · −1.2% vs ±40.1% expected
Headquarters
San Francisco, CA
Homepage
https://www.olema.com

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-7.07%-31.81%82.95%-5.03%9.69%1.74%8.41%
Feb-4.41%-33.33%-15.81%-18.69%-26.68%-5.65%-17.43%
Mar-17.93%-20.82%-13.47%-23.51%-10.69%-37.93%-20.72%
Apr-18.44%-37.80%37.25%-6.61%54.49%-4.70%4.03%
May8.37%6.72%-4.79%-6.92%-0.19%-7.89%-0.78%
Jun1.23%45.36%57.04%-7.99%-2.63%-1.57%15.24%
Jul-13.58%20.10%-1.26%45.06%17.62%-3.38%10.76%
Aug24.87%-20.20%11.78%-28.31%2.44%-7.54%-2.83%
Sep-6.83%-25.20%16.40%5.20%51.31%-18.18%3.78%
Oct-7.22%29.21%13.98%-6.26%-18.75%-15.36%-0.73%
Nov-67.59%-22.85%-6.63%-12.91%236.34%0.99%*21.22%
Dec-1.27%-14.04%-3.77%-42.90%-10.55%---14.51%
Total-80.53%-78.66%259.85%-75.91%380.61%-67.84%56.25%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $7.08
SMA 50: $8.30
SMA 200: $13.25
Current: $7.22
EMA 12: $7.22
EMA 26: $7.46
MACD: -0.2441 | Signal: 0.1202
BEARISH
ADX (14): 26.76
TREND
+DI: 17.50
−DI: 24.35

Momentum Oscillators

RSI (14): 46.01
NEUTRAL
Stoch %K: 75.79
Stoch %D: 73.40
Williams %R: -28.59

Volume & Volatility

BB Upper: $7.69
BB Lower: $6.48
NEUTRAL
OBV: 53,717,323
Vol SMA 20: 1,302,672
Vol ROC: -98.73%
ATR: $0.49
True Range: $0.17
HV 20: 81.0%
HV 30: 71.8%
HV 60: 61.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All OLMA news →
Earnings History
17 of 18 under expected move
Avg Expected Move
21.83%
Avg Actual Move
5.83%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-11-10 After-Close 15.87% 1.16% 0.07x Within
2022-02-28 After-Close 17.09% 14.96% 0.88x Within
2023-05-09 After-Close 24.90% 8.67% 0.35x Within
2023-08-08 After-Close 11.10% 12.05% 1.09x Exceeded
2023-11-07 After-Close 13.00% 3.13% 0.24x Within
2024-03-11 After-Close 12.15% 6.62% 0.54x Within
2024-05-08 After-Close 13.82% 9.31% 0.67x Within
2024-08-06 Pre-Market 30.46% 0.50% 0.02x Within
2024-11-12 After-Close 30.76% 0.52% 0.02x Within
2025-03-18 After-Close 24.15% 0.72% 0.03x Within
2025-05-13 After-Close 49.15% 3.85% 0.08x Within
2025-08-11 After-Close 17.51% 16.19% 0.92x Within
2025-11-10 Pre-Market 27.84% 4.19% 0.15x Within
2026-01-12 After-Close 7.29% 3.13% 0.43x Within
2026-03-17 After-Close 8.30% 3.25% 0.39x Within
2026-05-12 After-Close 12.17% 2.79% 0.23x Within
2026-08-10 After-Close 37.27% 12.65% 0.34x Within
2026-11-09 After-Close 40.08% 1.22% 0.03x Within

Earnings calendar: this week’s reports with expected vs actual moves →

OLMA Options Activity & IV Rank

OLMA IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 109.8%
7-DTE IV: —
Expected Move: $3.57
7-DTE Move: $3.70
Days to Exp: 37 (2026-12-18)

Options Flow · All expiries

Call Volume: 3,581
Put Volume: 10,398
P/C Volume: 2.904
BEARISH
Call OI: 12,312
Put OI: 21,358
P/C OI: 1.735
Total OI: 33,670

ATM Options Pricing

ATM Call: $2.55
ATM Put: $1.02
Call %: 35.3%
Put %: 14.2%

Chain Summary

Chain Volume: 13,979
Chain OI: 33,670
Last Updated: 11/11/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 21st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
21%
vs own history
GEX tilt
-0.74
OI-weighted, today
Vanna tilt
-0.74
δ-sensitivity to IV
Charm tilt
+0.50
δ-decay vs time
Vanna tilt -0.74: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.50: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 10 ATM contracts, 9k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)15.4LowNov 11

Embed OLMA IV rank

OLMA's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$3.57Nov 11
Beta Analysis

Risk Metrics

Beta: 0.6968
Alpha: 54.58%
Correlation: 0.0620
R-Squared: 0.4%
Stock Volatility: 154.1%
Market Volatility: 13.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own OLMA
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$13.4M
0.02%
#680 of 1945+1406.1%13F
Duquesne Family Office Family office
Stanley Druckenmiller
$12.3M
0.28%
#60 of 860.0%13F
Citadel Hedge fund
Ken Griffin
$8.0M
0.00%
#1751 of 6285-29.1%13F
Rockefeller Capital Management Family office
Rockefeller family
$4K
0.00%
#4270 of 4729-52.7%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

OLMA Institutional Ownership (13F)

Filings for 2026-06-30 · 58 already for 2026-09-30
Diluted shares outstanding: 90,258,943 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

191 filers102,934,588 shares$1.26B value114.04% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 12,143,062 $151.91M 12.06% 13.45% 2026-06-30
2 Paradigm Biocapital Advisors LP 8,670,576 $108.47M 8.61% 9.61% 2026-06-30
3 Jupiter Topco LLC 7,094,413 $88.80M 7.05% 7.86% 2026-06-30
4 Bain Capital Life Sciences Investors, LLC 7,085,249 $88.64M 7.04% 7.85% 2026-06-30
5 BlackRock, Inc. Custodian 6,714,691 $84.00M 6.67% 7.44% 2026-06-30
6 BVF INC/IL 5,295,893 $66.25M 5.26% 5.87% 2026-06-30
7 Siren, L.L.C. 4,856,949 $60.76M 4.82% 5.38% 2026-06-30
8 State Street Corp 4,316,058 $53.99M 4.29% 4.78% 2026-06-30
9 Vanguard Capital Management LLC 3,341,217 $41.80M 3.32% 3.70% 2026-06-30
10 Logos Global Management LP 3,208,875 $40.14M 3.19% 3.56% 2026-06-30
11 Franklin Resources, Inc. Custodian 2,349,586 $29.39M 2.33% 2.60% 2026-06-30
12 Cormorant Asset Management, LP 2,150,000 $26.90M 2.13% 2.38% 2026-06-30
13 Morgan Stanley Custodian 1,832,269 $22.92M 1.82% 2.03% 2026-06-30
14 Vanguard Portfolio Management LLC 1,663,218 $20.81M 1.65% 1.84% 2026-06-30
15 Goldman Sachs Group Inc Custodian 1,567,979 $19.62M 1.56% 1.74% 2026-06-30
16 Deep Track Capital, LP 1,500,000 $18.77M 1.49% 1.66% 2026-06-30
17 Geode Capital Management, LLC Custodian 1,969,909 $17.02M 1.35% 2.18% 2026-09-30
18 Lightspeed Management Company, L.L.C. 1,355,299 $16.95M 1.35% 1.50% 2026-06-30
19 KINGDON CAPITAL MANAGEMENT, L.L.C. 1,200,000 $15.01M 1.19% 1.33% 2026-06-30
20 Two Sigma Investments, LP Custodian 1,131,434 $14.15M 1.12% 1.25% 2026-06-30
21 Dimensional Fund Advisors LP Custodian 1,552,837 $13.42M 1.06% 1.72% 2026-09-30
22 Point72 Asset Management, L.P. 1,070,949 $13.40M 1.06% 1.19% 2026-06-30
23 Duquesne Family Office LLC 986,827 $12.35M 0.98% 1.09% 2026-06-30
24 Defilade Capital Management, L.P. 924,758 $11.57M 0.92% 1.02% 2026-06-30
25 Ameriprise Financial, Inc. Custodian 840,646 $10.52M 0.83% 0.93% 2026-06-30
10 filers$6.96M notional
# Filer Notional Value % of Total Period
1 Ikarian Capital, LLC $2.50M 35.96% 2026-06-30
2 Susquehanna International Group, LLP Custodian $1.30M 18.64% 2026-06-30
3 Citadel Advisors LLC Custodian $691.80K 9.94% 2026-06-30
4 BOOTHBAY FUND MANAGEMENT, LLC $688.05K 9.89% 2026-06-30
5 NOMURA HOLDINGS INC $505.40K 7.26% 2026-06-30
6 Jane Street Group, LLC Custodian $401.57K 5.77% 2026-06-30
7 Caption Management, LLC $375.30K 5.39% 2026-06-30
8 Point72 Asset Management, L.P. $252.70K 3.63% 2026-06-30
9 Simplex Trading, LLC Custodian $151.20K 2.17% 2026-09-30
10 GROUP ONE TRADING LLC Custodian $92.57K 1.33% 2026-06-30
9 filers$4.80M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $2.28M 47.48% 2026-06-30
2 NOMURA HOLDINGS INC $825.66K 17.19% 2026-06-30
3 GROUP ONE TRADING LLC Custodian $452.86K 9.43% 2026-06-30
4 Caption Management, LLC $375.30K 7.81% 2026-06-30
5 Citadel Advisors LLC Custodian $356.54K 7.42% 2026-06-30
6 Jane Street Group, LLC Custodian $325.26K 6.77% 2026-06-30
7 Jefferies Financial Group Inc. $129.60K 2.70% 2026-09-30
8 Simplex Trading, LLC Custodian $30.24K 0.63% 2026-09-30
9 Point72 Asset Management, L.P. $27.52K 0.57% 2026-06-30

OLMA Insider Trading (Form 4)

Latest: 2026-09-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-02 Jason O'Byrne CHIEF FINANCIAL OFFICER Grant (A) +650,000 opt — EDGAR
2026-07-27 Cyrus Harmon Director Sell (S) −25,000 $11.65 -$291.2K EDGAR
2026-06-23 G. Walmsley Graham Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Prakash Raman Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Ian T Clark Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Gorjan Hrustanovic Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Cynthia M Butitta Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Andrew Rappaport Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Yi Larson Director Grant (A) +29,500 opt — EDGAR
2026-06-23 J. Scott Garland Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Sandra Horning Director Grant (A) +29,500 opt — EDGAR
2026-06-23 Cyrus Harmon Director Grant (A) +29,500 opt — EDGAR
2026-06-23 BVF GP HOLDINGS LLC Director Award (A) — — EDGAR
2026-04-29 Prakash Raman Director Grant (A) +27,061 opt — EDGAR
2026-03-05 Shawnte Mitchell CHIEF LEGAL OFFICER Mixed
Sell −40,000 · Exer +40,000
 — $14.08 -$776.7K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

OLMA Insider Holdings

15 insiders · @ $7.22
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Bain Capital Life Sciences Opportunities IV, L.P. 10%+ Owner 7,800,000 $56.35M $1.73M 1 2025-01-13
2 BVF INC/IL Director 2,103,522 $15.20M $0 1 2025-06-13
3 BVF GP HOLDINGS LLC Director 2,103,522 $15.20M $22.57M 4 2026-06-23
4 G. Walmsley Graham Director 1,800,000 $13.00M -$15.45M 16 2026-06-23
5 Cyrus Harmon Director 819,798 $5.92M -$6.52M 39 2026-07-27
6 David C. Myles CH. DISCOV. & NON-CLIN DEV OFF 687,807 $4.97M -$5.61M 15 2026-02-04
7 BIOTECHNOLOGY VALUE FUND L P Director 470,266 $3.40M $0 1 2024-12-04
8 BVF I GP LLC Director 447,526 $3.23M $0 1 2025-01-14
9 Andrew Rappaport Director 421,833 $3.05M $0 11 2026-06-23
10 Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. 239,727 $1.73M -$3.57M 15 2026-01-15
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

OLMA Board & Officers

As of SEC filings through Sep 2, 2026

Directors 21

Officers 6

Changes in the last 10 years (81)
Aug 11, 2026Jason O'Byrne became Chief Financial Officer
Apr 28, 2026Prakash Raman became a director
Jan 30, 2026The company announced the departure of Shane William Charles Kovacs as Ch. Operating & Financial Off. in an SEC filing
Jan 30, 2026Sasha Lu Austin became VP of Finance and Controller
Feb 18, 2025Shawnte Mitchell became Chief Legal Officer
Jan 13, 2025Bain Capital Life Sciences Opportunities IV, L.P. reported in an SEC filing no longer being a 10% owner
Jan 13, 2025Bain Capital Life Sciences Opportunities IV GP, LLC reported in an SEC filing no longer being a 10% owner
Jan 13, 2025Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a 10% owner
Jan 13, 2025Bain Capital Life Sciences IV General Partner, LLC reported in an SEC filing no longer being a 10% owner
Jan 13, 2025Bain Capital Life Sciences Fund IV, L.P. reported in an SEC filing no longer being a 10% owner
Jan 8, 2025Bain Capital Life Sciences Opportunities IV, L.P. became a 10% owner
Jan 8, 2025Bain Capital Life Sciences Opportunities IV GP, LLC became a 10% owner
Jan 8, 2025Bain Capital Life Sciences Investors, LLC became a 10% owner
Jan 8, 2025Bain Capital Life Sciences IV General Partner, LLC became a 10% owner
Jan 8, 2025Bain Capital Life Sciences Fund IV, L.P. became a 10% owner
Dec 4, 2024Mark N Lampert no longer listed as a 10% owner in SEC filings
Dec 4, 2024Bvf Partners L P/il no longer listed as a 10% owner in SEC filings
Dec 4, 2024Bvf Inc/il no longer listed as a 10% owner in SEC filings
Dec 4, 2024Bvf Gp Holdings LLC no longer listed as a 10% owner in SEC filings
Aug 5, 2024Senai Asefaw reported in an SEC filing no longer being a 10% owner
Not reported recently (3)
  • John B Moriarty · Last reported as EVP, Ch. Legal Officer & Sec. in an SEC filing dated Feb 2, 2023
  • Kinney Horn · Last reported as Chief Business Officer in an SEC filing dated Feb 2, 2023
  • Frank McCormick · Last reported as a director in an SEC filing dated Nov 23, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

OLMA Proposed Insider Sales (Form 144)

Latest: 2026-07-24
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-07-24 Harmon Cyrus Director 12,500 $146.4K 2026-07-24 Fidelity Brokerage Services LLC — EDGAR
2026-07-23 Harmon Cyrus Director 12,500 $144.7K 2026-07-23 Fidelity Brokerage Services LLC — EDGAR
2026-03-16 Kovacs Shane William Charles Former Officer 4,166 $69.2K 2026-03-16 Fidelity Brokerage Services LLC — EDGAR
2026-03-16 Kovacs Shane William Charles Former Officer 100,000 $1.61M 2026-03-16 Fidelity Brokerage Services LLC — EDGAR
2026-03-11 Kovacs Shane William Charles Former Officer 50,000 $796.8K 2026-03-11 Fidelity Brokerage Services LLC — EDGAR
2026-03-10 Kovacs Shane William Charles Former Officer 53,206 $904.6K 2026-03-10 Fidelity Brokerage Services LLC — EDGAR
2026-03-09 Kovacs Shane William Charles Former Officer 241,999 $3.25M 2026-03-09 Fidelity Brokerage Services LLC — EDGAR
2026-03-04 Kovacs Shane William Charles Former Officer 20,000 $488.7K 2026-03-04 Fidelity Brokerage Services LLC — EDGAR
2026-03-04 Mitchell Shawnte Officer 25,000 $598.5K 2026-03-04 Fidelity Brokerage Services LLC — EDGAR
2026-03-03 Mitchell Shawnte Officer 15,000 $345.2K 2026-03-03 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-10
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-10 Earnings results EDGAR
2026-10-15 Director or officer change EDGAR
2026-08-13 Director or officer change · Regulation FD disclosure EDGAR
2026-08-10 Earnings results EDGAR
2026-06-23 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-10 0001193125-26-454421 EDGAR
2026-08-10 0001193125-26-342383 EDGAR
ETF Holders
53 ETFs hold OLMA
25 shown · $98.71M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $22.6M — 2026-09-30
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.15% $16.2M $10.5B 2026-11-09
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $14.9M $77.8B 2026-11-09
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $7.1M — 2026-09-30
5 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.03% $4.5M $14.1B 2026-11-09
6 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $4.2M — 2026-11-09
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.03% $4.0M $11.3B 2026-11-09
8 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $3.9M — 2026-09-30
9 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.05% $3.6M $6.8B 2026-11-09
10 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $2.8M — 2026-08-31
11 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $2.6M — 2026-11-09
12 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.14% $1.7M $1.2B 2026-11-09
13 VHT Vanguard Health Care ETF Vanguard 0.01% $1.4M — 2026-09-30
14 DFMC Dimensional US Micro Cap ETF Dimensional 0.02% $1.4M — 2026-11-09
15 SBIO ALPS Medical Breakthroughs ETF Nport 0.47% $1.1M — 2026-08-31
16 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.01% $928,214 $14.1B 2026-11-09
17 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $893,592 $95.3B 2026-11-09
18 CANC Tema Oncology ETF Nport 0.41% $871,239 — 2026-08-31
19 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.03% $813,522 — 2026-07-31
20 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $743,441 — 2026-11-09
21 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.10% $605,220 — 2026-11-10
22 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.04% $518,452 — 2026-09-30
23 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.03% $470,423 — 2026-07-31
24 BBC Virtus Biotech Clinical Trials Etf Nport 0.78% $360,560 — 2026-07-31
25 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $292,040 — 2026-08-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.03
TTM Revenue
—
TTM Net Income
$-185.15M
TTM Op. Cash Flow
$-148.72M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-53.09M$-0.52$-45.99M
Q4 '252025-12-31—$-46.06M$-0.51$-38.33M
Q3 '252025-09-30—$-42.22M$-0.49$-34.53M
Q2 '252025-06-30—$-43.78M$-0.51$-29.88M
Q1 '252025-03-31—$-30.39M$-0.36$-43.98M
Q4 '242024-12-31—$-33.57M$-0.40$-26.28M
Q3 '242024-09-30—$-34.55M$-0.60$-27.02M
Q2 '242024-06-30—$-30.38M$-0.54$-27.55M
Q1 '242024-03-31—$-30.97M$-0.56$-23.50M
Q4 '232023-12-31—$-26.77M$-0.48$-18.48M
Q3 '232023-09-30—$-21.50M$-0.48$-22.74M
Q2 '232023-06-30—$-20.09M$-0.49$-22.12M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.34
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-38.5%
ROA
-34.9%
Div Yield
0.00%
FCF Yield
-23.08%
Debt/Equity
0.01
Current Ratio
—
Market Cap
$644.45M
as of 2026-11-11

OLMA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.26T 46.2 +45.5% +31.7% 36
ABBV ABBVIE INC. $518.4B 50.1 +10.7% +27.0% 38
RVMD Revolution Medicines, Inc. Common Stock $43.3B — — +143.4% 60
CGON CG Oncology, Inc. Common stock $6.7B — +666.0% +75.2% 100
COGT Cogent Biosciences, Inc. Common Stock $5.8B — — −9.5% 100
RLAY Relay Therapeutics, Inc. Common Stock $4.5B — +23.9% +144.6% 39
IDYA IDEAYA Biosciences, Inc. Common Stock $3.1B — −83.0% −6.1% 59
IMNM Immunome, Inc. $2.3B — — −8.6% 66
OLMA Olema Pharmaceuticals, Inc. Common Stock $644M — — −71.4% 15
Peer median $6.3B 48.2 +23.9% +29.3% 59

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
15.68M
SI % of Float
24.81%
Days to Cover
13.38
Short Vol Ratio
68.9%
Free Float
63.20M
Float %
72.2%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-10-16